Copyright
©The Author(s) 2015.
World J Neurol. Mar 28, 2015; 5(1): 39-46
Published online Mar 28, 2015. doi: 10.5316/wjn.v5.i1.39
Published online Mar 28, 2015. doi: 10.5316/wjn.v5.i1.39
Table 1 Case series of rituximab in neuromyelitis optica
Ref. | Country; Type of study | No. of patients (n = 209) | Mean age at RTX; % Female | % Anti-AQP4 Ab seropositive | RTX Protocol /treatment duration | ARR before RTX | ARR after RTX | % Relapse-free | EDSS (median) before --> after RTX |
Cree et al[20] | United States; Retrospective | 8 | 371; 88% | N/A | A- treatment B- retreatment | 2.6 (median) | 0 (median) | 75% (6/8 pts at 12 mo f/u) | 7.5--> 5.5 |
Jacob et al[23] | United States/England; Retrospective | 25 | 431; 88% | 70% | A or B; median interval between cycles-8 mo 19 mo follow up | 1.7 (median) | 0 (median) | 72% (17/25 at 12 mo estimated) | 7--> 5 2 patients deceased |
Bomprezzi et al[31] | United States; Retrospective | 18 | 46 (+/-12); 83% | 67% | B | 15 pts-RTX tx and 7 had relapses. 42% (5/12) showed “positive treatment effects”, the other 7 continued to relapse despite RTX therapy | 53% (8/15) | Severe disability from NMO’ - 10 patients | |
Bedi et al[24] | United States; Retrospective | 23 | 461; 91% | 72% | A or B; 32.5 mo | 1.87 (median) | 0 (median) | 74 % (17/23 pts) | 7--> 5.5 |
Pellkofer et al[30] | Germany; Prospective | 10 | 471; 90% | 100% | B; number of cycles of RTX 1-5 | Ever before RTX: 1.3 mo, 12 m before RTX: 2.4 mo, 24 m before RTX: 1.72 mo, With RTX: 0.93 mo | 50% (5/10 at 12 mo estimated) | 6--> 6.51 1 patient deceased | |
Javed et al[22] | United States; Retrospective | 15 | 34; N/A | N/A | B; patients were given RTX 1g x1 usually 6-9 mo after the initial dose | 2/10 had 2 relapses in 6 mo post RX. 5 non-responders had mean of 1.45 (median 1) relapses in mean 12.2 (median 10) mo | 67% (RTX delayed further relapses for 9 mo or more) | N/A | |
Gredler et al[26] | Austria; Retrospective | 6 | 38; 83% | 66% | 375 mg/m2; no of infusions 3-16 (mean = 6.67), interval between infusions 3.3-11 mo | 2.5 (mean)1 | 0.4 (mean)1 | 67% (4/6) | 5.25--> 2.251 |
Ip et al[25] | China; Prospective | 7 | 52; 85% | 66% | A or B: Mean # trx courses: 2.85. median 2 | Mean ARR = 2.4 median ARR = 21 5 became relapse free. 2 had 50% reduction over median 24 mo | 71 % (5/7) | 8--> 7 | |
Lindsey et al[32] | United States; Retrospective | 9 | N/A; 89% | 60% | A or B: Mean duration: 74.2 mo | 3 pts with early relapses in first month after RTX, 4 pts (including 1 pt with early relapse) with later relapses | 33% (3/9) | 3.5--> 4.31 | |
Kim et al[27] | South Korea; Retrospective | 30 | 38.4 (± 10.5); 90% | 77% | A or B; mean 61 mo (range 49-82 mo), median 60 mo | 2.4 (mean) | 0.3 (mean) | 70% (21/30 at 2 yr f/u) | 4--> 3 |
Yang et al[28] | China; Prospective | 5 | 421; N/A | 80% | 100 mg (50-59 mg/m2) RTX IV 1 dose/wk for 3 cons wk; mean duration: 12.2 mo | 1.161 (mean) | 01 (mean) | 100% | 4.5--> 4 |
Mealy et al[29] | United States; Retrospective | 30 | 451; 83% | 50% | B; median of 20 mo (range 5-83 mo) | Total pretreatment ARR- 2.89 | Total post-treatment ARR- 0.33 | 67% (20/30) | N/A |
Farber et al[21] | United States; Retrospective | 23 | 38; 100% | 74% | Mean of 22 mo (range 2-96 mo) | Median ARR was 0.24; mean was 1.02 (SD = 1.36) | 48% (11/23) | N/A |
- Citation: Wong E, Vishwanath VA, Kister I. Rituximab in neuromyelitis optica: A review of literature. World J Neurol 2015; 5(1): 39-46
- URL: https://www.wjgnet.com/2218-6212/full/v5/i1/39.htm
- DOI: https://dx.doi.org/10.5316/wjn.v5.i1.39